A recent analysis reveals striking disparities in the cost and availability of cancer drugs across different regions of the globe, with significant gaps between high- and low-income countries.

By now, we’ve all heard of the GLP-1 diabetes and weight-loss drugs from the likes of Eli Lilly (LLY) and Novo Nordisk (NVO).

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

Drug manufacturers have increased their production, and some such as Novo Nordisk have asked the FDA to ban further production of compounded versions of their drugs. If that happens, Lavin says many ...

If you’ve noticed ads for weight loss injections flood your social media feeds, you’re not alone. The soaring popularity of ...

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Today it is happening again with GLP1 agonists like Semaglutide with the brand names of Wegovy ... He is concerned about the financial costs and health risks potentially posed by these drugs. There is ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

For those who have struggled with the scale, the treatments can help achieve results and improve overall health (and do so ...